Key Takeaways
- Strong Q1, led by non-urea businesses: Standalone EBITDA grew 21% YoY to INR 942 crore, driven by a 40% surge in CPC-SN contribution profit and better-than-expected energy savings in urea.
- Traded fertiliser margins flattered by a one-off: The sharp jump in complex fertiliser margins included a INR 92 crore prior-period subsidy receipt; underlying performance was comparable to last year on lower volumes.
- CPC-SN is the growth engine, but margin volatility is structural: Revenue grew ~27% on new molecules and volumes, while contribution margin swung to 23% against an 18% guided floor; management insists the 18-23% band will persist.
- Seeds entry is serious but deliberately opaque: Planning is "quite advanced" with resources being gathered, yet crop targets, timelines and the organic-vs-inorganic mix remain undisclosed; clarity is promised in the next one or two quarters.
- What to watch next quarter: Whether CPC-SN margins hold near 23% or revert toward 18%, any concrete colour on the seeds business, and the trajectory of IMACID's performance as DAP prices firm up.
CPC-SN: The Growth Engine
- Contribution profit up 40%: Driven by an advanced placement scheme that captures shelf space early, good product selection, volume growth, and an uptick from biologicals.
- Revenue breakdown: Gross sales up ~27%, composed of 17% growth from new molecules, 17% from volume increase in the existing portfolio, and a 7% drag from price declines.
- Product pipeline active: 8 new CPC offerings launched in Q1 (6 weedicides, 2 fungicides), with 4 more products added to the pipeline this financial year.
- Combination products as a moat: A new Imazethapyr + Quizalofop-P-ethyl combination from Nissan was launched; Chambal is only the third company permitted to market it, limiting competitive pressure.
- Asset-light manufacturing, for now: The company uses toll manufacturers and is not currently pursuing its own CPC manufacturing, though it keeps evaluating the option as scale builds.
- Channel depth target: Management aims for roughly 30% depth and width in its distribution network to support future growth projections.
- Margin volatility is accepted as normal: Contribution margin swung from 18% to 23% this quarter; management will not raise its FY27 guidance of 18%, stating the 18-23% band will keep recurring and they will deliver consistently over time.
Baijal: "To cut a long story short, the fact is, tactics do not only dictate. There is product value. There is a value on the table in terms of what the product actually delivers."
Urea: Steady, with Energy Gains
- Optimal capacity utilisation: All urea units operated at full capacity during the quarter.
- Energy savings exceeding expectations: Schemes implemented during the March 2024 Annual Turnaround at Gadepan-1 and II are delivering better-than-anticipated results, lowering the energy cost base.
- Throughput increase completed: The 110 metric-ton-per-day capacity expansion at the urea plant has already been achieved.
- Energy roadmap is continuous: One part of the energy-saving program has been executed to meet the 2026 ATR timeline; further schemes are under evaluation with an ambition to be best-in-class, though no specific timeline is set.
- Gadepan-III benefits distant: No conversation with the government has begun; discussions are expected to start late in FY25, with 2.5 years still remaining before any benefit materialises.
Traded Fertilisers: One-Off Masked Underlying Softness
- Segment profit inflated by a prior-period item: The INR 90 crore jump in complex fertiliser margins (INR 30 cr to INR 120 cr) is almost entirely explained by a INR 92 crore prior-period subsidy receipt; stripping that out, comparable quarter-on-quarter numbers were flat, with volumes slightly lower this year.
- Subsidy receipts declined: Overall subsidy received fell YoY because commodity prices have dropped; DAP subsidy was down roughly INR 10,000 per ton on far lower volumes, and MOP subsidy fell INR 7,000-8,000.
- Segment assets fell sharply: Both QoQ and YoY, driven by seasonality and lower DAP volumes, which left stocks lower than the same quarter last year.
- No guidance on complex fertiliser margins: Management declined to forecast segment results, citing three open variables: government MRP policy, international prices, and subsidy decisions, all of which require tactical agility.
Baijal: "This is very dynamic. I cannot give you any guidance on this actually because there are two factors in play. One is the government's own policy decision on MRP. Second is the international prices. Third is the subsidy that they decide. When everything is open, you have to be exceedingly tactical on this."
New Business Bets: Seeds & Biologicals
- Seeds entry is a serious, multi-year move: Planning is "quite advanced" with men, material and resources being gathered; the approach will begin organically, with inorganic options evaluated later.
- Deliberate secrecy on crop targets: Management declined to disclose which crops the seeds business will target, calling it "a secret for the moment."
- Timeline has a 3-5 year research cycle: Hybrid seed research takes 3-5 years; in the interim, licensing and other options will be used to generate products, with clarity expected in the next one or two quarters.
- "Uttam Pranaam" Bio Nano Phosphorus: Differentiated by a biogenic process using bacteria to convert rock phosphate to phosphorus while eliminating trace elements; initial results are good, and steeper growth is expected from next year as acceptance builds.
- Biological pipeline building: New biological fungicides and a Nematicide are in trials, targeted for launch over the next 6-12 months; eco-friendly bio-stimulants are also under analysis with a variant expected in the near future.
Srivastava: "This is the only product in the ecosystem which comes from a bio-process. A bacteria helps conversion to phosphorous from rock phosphate and at the same time eliminating the trace elements."
IMACID & Other JV Updates
- IMACID performed well: Higher production and better margins were delivered, helped by softer input prices; production was higher YoY.
- Near-term outlook constructive: Management believes Q1 performance could repeat in Q2 and possibly beyond, subject to no production blackouts, with DAP prices firming up and phosphoric acid prices expected to remain stable.
- TAN project progressing: All statutory approvals are in place, orders for long-lead items have been placed, and construction is advancing well.
- Nitric acid value chain under review: Initial estimates for a nitric acid plant came in higher than expected; management is relooking at numbers with another party and will revert once a satisfactory figure is reached.
- Zero debt achieved: Long-term loans were prepaid after receiving approximately INR 2,300 crore in subsidies.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CPC-SN contribution margin floor | Maintain at least 18% despite quarterly volatility up to 23% | FY27 |
| New biological products launch | Fungicides and Nematicide products to be launched | Next 6-12 months |
| Seeds business clarity | Concrete details on entry strategy, crops, and approach to be disclosed | Next 1-2 quarters |
| IMACID performance | Q1-level performance could repeat, subject to no production blackouts | Q2 and possibly beyond |
| Gadepan-III benefit discussions | Conversations with government to begin | Late FY25 |
| Energy-saving roadmap | Further schemes continuously evaluated; one part executed to meet 2026 ATR timeline | 2026 (ATR deadline) |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Standalone EBITDA | ₹942 cr, +21% YoY |
| Standalone PAT | ₹552 cr, +18% YoY |
| Consolidated PAT | ₹448 cr, +32% YoY |
| Urea production | 9.23 lakh MT |
| Subsidies received | ₹2,300 cr |
| Net debt | Zero |
| CPC-SN net revenue | ₹343 cr, up from ₹296 cr in Q1 FY24 |
| CPC-SN contribution margin | ~23%, vs FY27 guidance of ~18% |
| CPC gross sales growth | ~27%, comprising 17% from new molecules, 17% from existing portfolio volume increase, offset by 7% price decline |
| Traded fertiliser segment margin | ₹120 cr, up from ₹30 cr YoY, includes ₹92 cr prior-period income |
| TAN project cumulative spend | ₹342 cr till June 30, 2024 |
| Urea capacity increase (G-I, G-II) | 110 MTPD throughput increase achieved |
| Uttam Pranaam sales | 19,000 litres (76,000 bottles), turnover of ₹2.0 cr, 76,000 acres treated |
| CPC cash sales mix | 66% cash, 34% credit |
| SN cash sales mix | 36% cash, 64% credit |